BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Landfeldt E, Sejersen T, Tulinius M. A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy. Acta Paediatr 2019;108:224-30. [PMID: 30188594 DOI: 10.1111/apa.14568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Käll A, Lagercrantz H. Highlights in this issue. Acta Paediatr 2019;108:196-7. [DOI: 10.1111/apa.14698] [Reference Citation Analysis]
2 Saifullah, Motohashi N, Tsukahara T, Aoki Y. Development of Therapeutic RNA Manipulation for Muscular Dystrophy. Front Genome Ed 2022;4:863651. [DOI: 10.3389/fgeed.2022.863651] [Reference Citation Analysis]
3 Blonda A, Barcina Lacosta T, Toumi M, Simoens S. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries. Front Pharmacol 2021;12:750742. [PMID: 35126102 DOI: 10.3389/fphar.2021.750742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lim KRQ, Yoon C, Yokota T. Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy. J Pers Med 2018;8:E38. [PMID: 30477208 DOI: 10.3390/jpm8040038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
5 Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs 2021;30:167-76. [PMID: 33393390 DOI: 10.1080/13543784.2021.1868434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Benassi A, Doria F, Pirota V. Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds. Int J Mol Sci 2020;21:E8692. [PMID: 33217987 DOI: 10.3390/ijms21228692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Politano L. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update. Acta Myol 2021;40:43-50. [PMID: 33870095 DOI: 10.36185/2532-1900-041] [Reference Citation Analysis]